MELISSA GOODEMOTE: Open Payments
NPI 1124117403 · ALBANY, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$730 in 12 payments from 6 companies in 2025. Trend: 2023 $200 · 2024 $764 · 2025 $730
Food & beverage: $730
| Company | Payments | Amount |
|---|---|---|
| Otsuka America Pharmaceutical, Inc. | 4 | $185 |
| Teva Pharmaceuticals USA, Inc. | 3 | $159 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $143 |
| ABBVIE INC. | 1 | $123 |
| Vanda Pharmaceuticals Inc. | 1 | $102 |
| Neurocrine BioSciences, Inc. | 1 | $19 |
Products named: REXULTI, AUSTEDO XR, CAPLYTA, VRAYLAR, FANAPT, INGREZZA.
Industry payments across NY — which companies pay providers there.
